Literature DB >> 15083285

Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.

Halina Bartosik-Psujek1, Juan J Archelos.   

Abstract

Recently it has been shown that axonal damage occurs in all stages of multiple sclerosis (MS) and can be detected very early in the course of the disease. Axonal pathology has been related to the inflammatory demyelinating environment, but its dependence on inflammation is still unknown. We measured tau protein and 14-3-3, two intracellular proteins expressed in neurons and glial cells, in the cerebrospinal fluid (CSF) of 114 patients with MS, in 79 patients with other inflammatory neurological diseases (IND) and in the CSF of 60 patients with non-inflammatory neurological diseases (NIND) as controls. Concentrations of tau protein and 14-3-3 were measured by enzymelinked immunoassay and were correlated to the following immune parameters in the CSF: leukocyte cell count, total protein, albumin CSF/serum ratio as a marker of disruption of the blood-brain barrier, immunoglobulin (IgG concentrations and IgG index as an indicator for intrathecal synthesis of IgG in the CSF). Both in MS and IND tau protein levels were significantly higher than in NIND (p<0.05). In MS patients levels of tau protein were positively correlated with the IgG index (p<0.05) and this association was present in both relapsing remitting MS (RRMS) (p<0.05) and progressive MS (p<0.05). Tau and 14-3-3 were also correlated with the IgG index in patients with IND (p<0.05). These findings strengthen the hypothesis that inflammation may be at least in part responsible for the axonal damage observed in MS patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083285     DOI: 10.1007/s00415-004-0336-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  14-3-3s are potential biomarkers for HIV-related neurodegeneration.

Authors:  Diana Morales; Efthimios C M Skoulakis; Summer F Acevedo
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

Review 4.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

5.  A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases.

Authors:  Krishnakumar N Menon; David L Steer; Martin Short; Steven Petratos; Ian Smith; Claude C A Bernard
Journal:  Mol Cell Proteomics       Date:  2011-03-18       Impact factor: 5.911

Review 6.  Recent advances in phosphoproteomics and application to neurological diseases.

Authors:  Justine V Arrington; Chuan-Chih Hsu; Sarah G Elder; W Andy Tao
Journal:  Analyst       Date:  2017-11-20       Impact factor: 4.616

Review 7.  [Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature].

Authors:  T Leyhe; C Laske; G Buchkremer; H Wormstall; H Wiendl
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 8.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

Review 10.  Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

Authors:  Alberto Gajofatto; Matilde Bongianni; Gianluigi Zanusso; Maria Donata Benedetti; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2011-11-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.